Fortress Biotech (FBIO) and its majority-owned subsidiary, Helocyte, announced that the first patient was dosed in a multicenter, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback